Influence of calcium chloride and aprotinin in the in vivo biological performance of a composite combining biphasic calcium phosphate granules and fibrin sealant.
Highly bioactive biomaterials have been developed to replace bone grafts in orthopedic revision and maxillofacial surgery for bone augmentation. A mouldable, self-hardening material can be obtained by combining TricOs Biphasic Calcium Phosphate Granules and Tissucol Fibrin Sealant. Two components, calcium chloride and antifibrinolytic agents (aprotinin), are essential for the stability of the fibrin clot. The ingrowth of cells in composites combining sealants without calcium chloride or with a low concentration of aprotinin was evaluated in vivo in an experiment on rabbits. Bone colonization was compared using TricOs alone or with the composite made from TricOs and the standard fibrin sealant. Without the addition of calcium chloride, the calcium ions released by the ceramic component interacted with the components of the sealant too late to stabilize the clot. With a low concentration of aprotinin, the degradation of the clot occurred more quickly, leading to the absence of a scaffold on which the bone cells could colonize the composite. Our results indicate that a stable fibrin scaffold is crucial for bone colonization. The low calcium chloride and low aprotinin groups have shown lower bone growth. Further studies will be necessary to determine the minimal amount of antifibrinolytic agent (aprotinin) necessary to allow the same level of osteogenic activity as the TricOs-fibrin glue composite.
Le Guehennec
Laurent
L
INSERM, EMI 9903 Materials of Biological Interest, Nantes University, Dental Faculty, place A. Ricordeau, BP 84215, 44042 Nantes Cedex, France.
Goyenvalle
Eric
E
Aguado
Eric
E
Pilet
Paul
P
Spaethe
Reiner
R
Daculsi
Guy
G
D000818:Animals; D007611:Aprotinin / Q000008:administration & dosage* / Q000737:chemistry; D018786:Bone Substitutes / Q000737:chemistry / Q000627:therapeutic use*; D002122:Calcium Chloride / Q000737:chemistry; D002130:Calcium Phosphates / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry; D005260:Female; D005264:Femoral Fractures / Q000473:pathology* / Q000601:surgery*; D015718:Fibrin Tissue Adhesive / Q000737:chemistry / Q000627:therapeutic use*; D017102:Fracture Healing / Q000187:drug effects; D008422:Materials Testing; D016348:Osseointegration / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits; D016896:Treatment Outcome
D018786:Bone Substitutes; D002130:Calcium Phosphates; D004337:Drug Carriers; D015718:Fibrin Tissue Adhesive; D007611:Aprotinin; C485829:calcium phosphate, dibasic, anhydrous; D002122:Calcium Chloride